US' Section 301 Actions are Illegitimate and Misguided
On 23rd August, the US Administration imposed yet another set of discriminatory tariffs on China under its Section 301 Trade Act covering US$16 billion of its imports from China. This is in addition to the (more...)
The International Debate on Generic Medicines of Biological OriginBy Dr. Germán Velásquez
The debate on generic medicines is not new. What makes it different today is that attacks levelled against biological generic products are couched in even more “technical” and (more...)
A giant walks with us no more. Tribute to Dr. Samir Amin, 1931-2018
Professor Samir Amin passed away on Sunday, August 12, leaving a large gap among those luminaries of the South who offered critical thinking on the challenges facing developing countries and the (more...)
The Imperative of Protecting and Respecting Indigenous Peoples’ Rights to Their Traditional Knowledge, Traditional Cultural Expressions and Genetic Resources in the Intellectual Property Rights Regime under the WTO and WIPOBy Victoria Tauli-Corpuz
Victoria (more...)
Interaction of Transfer Pricing & Profit Attribution: Conceptual and Policy Issues for Developing CountriesBy Dr. Vinay Kumar Singh
Till 2010, model tax conventions treated profit attribution to permanent establishments and transfer pricing under different (more...)
Title: Side Event to the 71st World Health Assembly, on Access to Medicines: Overcoming Obstacles created by monopolies - Essential to UHC and the 2030 AgendaDate: (more...)
Title: Consultations with the United Nations Interagency Coordination Group on Antimicrobial Resistance (IACG) Subgroup 4 on Innovation and AccessDate: (more...)
